Taysha Gene Therapies EBITDA Margin 2020-2024 | TSHA

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Taysha Gene Therapies (TSHA) over the last 10 years. The current EBITDA margin for Taysha Gene Therapies as of September 30, 2024 is .
Taysha Gene Therapies EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-09-30 $0.01B $-0.09B -870.00%
2024-06-30 $0.01B $-0.08B -592.31%
2024-03-31 $0.01B $-0.08B -564.29%
2023-12-31 $0.02B $-0.07B -443.75%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.434B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00